Clinical trials
Alcoholic Liver Disease clinical trials
Below are recruiting alcoholic liver disease clinical trials, each written for real people, not researchers. We’re tracking 244 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06588699RecruitingPhase 2
Digoxin for NASH liver disease study
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
New Haven, ConnecticutAges 18–75 - NCT07824089Recruiting
Exercise training to reduce alcohol use and liver damage
This study tests whether a supervised exercise program can help people with alcohol-related liver disease drink less and reduce liver injury. It may work by boosting a natural hormone called FGF21, which helps regulate alcohol intake.
Cleveland, OhioAges 18 years+ - NCT04014413Recruiting
Fecal transplant for gut and immune-related conditions
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
Hong Kong, ShatinAges Any age - NCT05178069RecruitingPhase 2
Probiotic supplement study for alcohol use disorder and liver injury
This Phase 2 trial studies whether a probiotic (LGG) can improve health in people with alcohol use disorder and alcohol-related liver injury. It’s not an alcohol treatment study, so participants are mainly joining to see how the supplement affects the body and liver-related outcomes.
Louisville, KentuckyAges 21–65 - NCT02422238Recruiting
Study of fatty liver in adults, using MRI and stored samples
This study follows people with nonalcoholic fatty liver disease to better understand the condition. It uses an MRI scan and collects body samples to help researchers study changes over time.
Maastricht, LimburgAges 18–65 - NCT04971577RecruitingPhase 2/Phase 3
Simvastatin for alcohol-related liver scarring in stable adults
This trial studies whether simvastatin (a cholesterol medicine) can improve or slow scarring of the liver caused by long-term alcohol use. Participants must have confirmed liver fibrosis on biopsy and be in a stable (compensated) phase of liver disease.
BarcelonaAges 18 years+ - NCT07599241Recruiting
Exercise Program for Older Women With Thyroid, Eye, and Liver Conditions
This study tests whether a physical activity program can help older women manage three common conditions together: an underactive thyroid, high eye pressure (glaucoma), and fatty liver disease. Researchers want to see if exercise improves symptoms and overall health when addressing multiple conditions at once.
Dokki, Giza GovernorateAges 65–75 - NCT07359742Recruiting
Detecting liver scarring in chronic liver disease
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
BrusselsAges 18 years+ - NCT03875625Recruiting
Tracking body fat and liver fat after weight-loss treatment
This study looks at how body fat and liver fat change after bariatric (weight-loss) surgery or a lifestyle program. You may join if you have overweight or obesity and can safely have MRI scans, so researchers can compare results between treatment approaches.
Hong Kong, ShatinAges 18–65 - NCT06890039RecruitingPhase 2
Study of a new treatment for severe alcoholic hepatitis
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
London, Greater LondonAges 18–75 - NCT00983463Enrolling by invitation
Study of liver fats and proteins in fatty liver disease
This study measures different fats and proteins in the liver of people with fatty liver disease (often called NAFLD) who are having planned abdominal or weight-loss surgery. It may help doctors better understand what’s happening in the liver and improve future care.
Nashville, TennesseeAges 18–65 - NCT04873258Recruiting
Test a non-invasive tool to screen for fat-related liver disease
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
London, LondonAges 18–80 - NCT04781322RecruitingPhase 1
Study drug to reduce LDL cholesterol effects in heavy drinkers
This Phase 1 study tests how safe a cholesterol-lowering antibody (alirocumab) is in people who drink heavily but are not seeking alcohol treatment. It also looks at early drug effects in the body to see how it might change cholesterol-related signals.
Bethesda, MarylandAges 21–65 - NCT07481734RecruitingPhase 2
Tesamorelin for reducing liver fat in fatty liver disease
This trial tests if tesamorelin, a daily injection, can reduce liver fat in adults with fatty liver disease. It may help people whose liver has fat but is not yet scarred into cirrhosis.
Shenzhen, GuangdongAges 18–75 - NCT07400367Recruiting
Probiotics and lifestyle changes for fatty liver disease
This trial tests whether taking probiotics plus making lifestyle changes can improve fatty liver and metabolic health. You may qualify if you have liver fat and at least one sign of metabolic problems like high blood sugar or high blood pressure.
New Taipei CityAges 18–80 - NCT05895890Recruiting
Studying alcohol-related liver disease and addiction care
This study follows adults with alcohol-related liver disease to better understand and manage alcohol addiction and related health problems. You may be able to help researchers by sharing health information and consented care experiences.
Clamart, Île-de-France RegionAges 18–75 - NCT03209791Recruiting
Study alcohol-related effects on muscle recycling in the liver
This study looks at how alcoholic liver disease may change a natural body clean-up process in muscle. It compares people with alcoholic liver disease to people without it to better understand the biology and identify possible targets for treatment.
Cleveland, OhioAges 18–65 - NCT03224949Recruiting
Study comparing fatty liver types and healthy livers
This study compares liver samples and blood tests from people with alcohol-related fatty liver disease, alcohol-related hepatitis, and cirrhosis (including some with liver cancer) against healthy controls. It aims to better tell these liver conditions apart and understand what is different between them.
Cleveland, OhioAges 18–75 - NCT07832994Recruiting
Exercise for teens with celiac disease, metabolic syndrome, and fatty liver
This trial tests whether a specific exercise program can improve metabolic syndrome and fatty liver in teenage girls with celiac disease. It may help reduce liver fat and improve overall health.
Giza, DokkiAges 13–17 - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT05919680RecruitingPhase 2
NST-6179 for liver disease from intestinal failure in adults
This Phase 2 study tests NST-6179 in people who have intestinal failure–associated liver disease (IFALD). It aims to improve liver function and overall outcomes for people whose liver inflammation and lab tests have been abnormal for at least 6 months.
Scottsdale, ArizonaAges 16 years+ - NCT06935994RecruitingPhase 2
Aspirin for Fatty Liver Disease (MASLD)
This study tests whether aspirin can help people with MASLD, a type of fatty liver disease linked to conditions like diabetes and obesity. It aims to see if aspirin can improve liver health without causing harm.
Taichung, TaiwanAges 18 years+ - NCT05045482RecruitingPhase 1
Study drug in people with cirrhosis from blocked bile flow
This Phase 1 trial studies how saroglitazar magnesium works in people with liver scarring (cirrhosis) caused by a bile-flow problem. It helps doctors understand safety and how the body handles the medicine in this specific liver condition.
Indianapolis, IndianaAges 18–80 - NCT02897908Recruiting
Noninvasive scan to check liver fat and scarring
This study tests a noninvasive FibroScan machine to help measure liver fat and possible liver scarring using information collected in a database. It may help researchers improve how liver problems like fat buildup and scarring are identified and tracked.
Buffalo, New YorkAges 18 years+
Hear when a new Alcoholic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alcoholic liver disease?
- Yes. Clin2 currently lists 244 recruiting alcoholic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alcoholic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alcoholic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.